Lanzoni Giacomo, Roda Giulia, Belluzzi Andrea, Roda Enrico, Bagnara Gian Paolo
Department of Histology, Embryology and Applied Biology, University of Bologna, Via Belmeloro 8, Bologna, Italy.
World J Gastroenterol. 2008 Aug 7;14(29):4616-26. doi: 10.3748/wjg.14.4616.
The incidence and prevalence of Crohn's disease (CD) and ulcerative colitis (UC), the two major forms of inflammatory bowel diseases (IBD), are rising in western countries. The modern hygienic lifestyle is probably at the root of a disease where, in genetically susceptible hosts, the intestinal commensal flora triggers dysregulated immune and inflammatory responses. Current therapies ranging from anti-inflammatory drugs to immunosuppressive regimens, remain inadequate. Advances in our understanding of the cell populations involved in the pathogenetic processes and recent findings on the regenerative, trophic and immunoregulatory potential of stem cells open new paths in IBD therapy. Hematopoietic and mesenchymal stem cells are catalyzing the attention of IBD investigators. This review highlights the pivotal findings for stem cell-based approaches to IBD therapy and collects the encouraging results coming in from clinical trials.
克罗恩病（CD）和溃疡性结肠炎（UC）是炎症性肠病（IBD）的两种主要形式，在西方国家，它们的发病率和患病率正在上升。现代卫生的生活方式可能是这种疾病的根源，在基因易感性宿主中，肠道共生菌群会引发免疫和炎症反应失调。从抗炎药物到免疫抑制方案的现有疗法仍然不足。我们对参与发病过程的细胞群体的理解取得了进展，以及最近关于干细胞的再生、营养和免疫调节潜力的研究结果，为IBD治疗开辟了新途径。造血干细胞和间充质干细胞正在引起IBD研究人员的关注。这篇综述重点介绍了基于干细胞的IBD治疗方法的关键发现，并收集了来自临床试验的令人鼓舞的结果。
